CA2967607A1 - Methodes de modulation de l'apoptose par administration d'agonistes de relaxine - Google Patents

Info

Publication number

CA2967607A1

CA2967607A1 CA2967607A CA2967607A CA2967607A1 CA 2967607 A1 CA2967607 A1 CA 2967607A1 CA 2967607 A CA2967607 A CA 2967607A CA 2967607 A CA2967607 A CA 2967607A CA 2967607 A1 CA2967607 A1 CA 2967607A1

Authority

CA

Canada

Prior art keywords

relaxin

tissue

rlx

delivery

receptor

Prior art date

2000-10-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 108090000103 Relaxin Proteins 0.000 title claims abstract description 451
• 102000003743 Relaxin Human genes 0.000 title claims abstract description 447
• 230000006907 apoptotic process Effects 0.000 title claims abstract description 59
• 239000000556 agonist Substances 0.000 title claims description 29
• 238000000034 method Methods 0.000 title abstract description 113
• 239000005557 antagonist Substances 0.000 claims abstract description 37
• 210000001519 tissue Anatomy 0.000 claims description 200
• 108090000728 Relaxin receptors Proteins 0.000 claims description 184
• 102000004215 Relaxin receptors Human genes 0.000 claims description 182
• 210000004027 cell Anatomy 0.000 claims description 176
• 210000001550 testis Anatomy 0.000 claims description 57
• 201000010063 epididymitis Diseases 0.000 claims description 33
• 210000003734 kidney Anatomy 0.000 claims description 31
• 210000004185 liver Anatomy 0.000 claims description 31
• 210000005001 male reproductive tract Anatomy 0.000 claims description 30
• 210000000918 epididymis Anatomy 0.000 claims description 28
• 210000002307 prostate Anatomy 0.000 claims description 28
• 210000000952 spleen Anatomy 0.000 claims description 21
• 238000012360 testing method Methods 0.000 claims description 21
• 210000001541 thymus gland Anatomy 0.000 claims description 21
• 210000002216 heart Anatomy 0.000 claims description 19
• 210000004556 brain Anatomy 0.000 claims description 18
• 206010028980 Neoplasm Diseases 0.000 claims description 17
• 238000002347 injection Methods 0.000 claims description 17
• 239000007924 injection Substances 0.000 claims description 17
• 238000004519 manufacturing process Methods 0.000 claims description 16
• 230000007423 decrease Effects 0.000 claims description 15
• 238000001802 infusion Methods 0.000 claims description 13
• 201000011510 cancer Diseases 0.000 claims description 12
• 210000001625 seminal vesicle Anatomy 0.000 claims description 12
• 201000010653 vesiculitis Diseases 0.000 claims description 12
• 210000003679 cervix uteri Anatomy 0.000 claims description 11
• 210000003491 skin Anatomy 0.000 claims description 11
• 238000007920 subcutaneous administration Methods 0.000 claims description 11
• 210000002808 connective tissue Anatomy 0.000 claims description 9
• 206010020718 hyperplasia Diseases 0.000 claims description 9
• 230000003111 delayed effect Effects 0.000 claims description 7
• 210000002919 epithelial cell Anatomy 0.000 claims description 7
• 210000005002 female reproductive tract Anatomy 0.000 claims description 7
• 230000037317 transdermal delivery Effects 0.000 claims description 7
• 239000003814 drug Substances 0.000 claims description 6
• 210000003041 ligament Anatomy 0.000 claims description 6
• 230000009826 neoplastic cell growth Effects 0.000 claims description 6
• 210000001696 pelvic girdle Anatomy 0.000 claims description 6
• 230000001850 reproductive effect Effects 0.000 claims description 6
• 210000004291 uterus Anatomy 0.000 claims description 6
• 206010020880 Hypertrophy Diseases 0.000 claims description 5
• 210000002889 endothelial cell Anatomy 0.000 claims description 5
• 210000002950 fibroblast Anatomy 0.000 claims description 4
• 210000001616 monocyte Anatomy 0.000 claims description 3
• 210000000963 osteoblast Anatomy 0.000 claims description 3
• 108090000623 proteins and genes Proteins 0.000 abstract description 54
• 229940124165 Relaxin agonist Drugs 0.000 abstract description 31
• 230000005856 abnormality Effects 0.000 abstract description 31
• 229940121747 Relaxin antagonist Drugs 0.000 abstract description 28
• 230000035800 maturation Effects 0.000 abstract description 25
• 238000011161 development Methods 0.000 abstract description 14
• 150000007523 nucleic acids Chemical class 0.000 description 201
• 102000039446 nucleic acids Human genes 0.000 description 185
• 108020004707 nucleic acids Proteins 0.000 description 185
• 101150041885 rlx gene Proteins 0.000 description 174
• 108090000765 processed proteins & peptides Proteins 0.000 description 112
• 102000004196 processed proteins & peptides Human genes 0.000 description 102
• 229920001184 polypeptide Polymers 0.000 description 98
• 241000699670 Mus sp. Species 0.000 description 87
• 239000012634 fragment Substances 0.000 description 69
• 235000001014 amino acid Nutrition 0.000 description 56
• 229940024606 amino acid Drugs 0.000 description 55
• 150000001413 amino acids Chemical class 0.000 description 51
• 239000013598 vector Substances 0.000 description 47
• 230000014509 gene expression Effects 0.000 description 46
• 230000000694 effects Effects 0.000 description 44
• 210000005239 tubule Anatomy 0.000 description 44
• 241000282414 Homo sapiens Species 0.000 description 40
• 241001465754 Metazoa Species 0.000 description 38
• 102000053602 DNA Human genes 0.000 description 36
• 230000001965 increasing effect Effects 0.000 description 35
• 108020004414 DNA Proteins 0.000 description 34
• 230000000692 anti-sense effect Effects 0.000 description 33
• 230000027455 binding Effects 0.000 description 33
• 239000000203 mixture Substances 0.000 description 33
• 102000008186 Collagen Human genes 0.000 description 32
• 108010035532 Collagen Proteins 0.000 description 32
• 229920001436 collagen Polymers 0.000 description 32
• 239000002773 nucleotide Substances 0.000 description 32
• 125000003729 nucleotide group Chemical group 0.000 description 32
• 238000006467 substitution reaction Methods 0.000 description 32
• 238000010186 staining Methods 0.000 description 29
• 238000003556 assay Methods 0.000 description 28
• 238000000338 in vitro Methods 0.000 description 27
• 239000013543 active substance Substances 0.000 description 26
• -1 omithine Chemical compound 0.000 description 24
• 125000003275 alpha amino acid group Chemical group 0.000 description 22
• 239000013604 expression vector Substances 0.000 description 22
• 230000015572 biosynthetic process Effects 0.000 description 20
• 238000001727 in vivo Methods 0.000 description 20
• 102000055102 bcl-2-Associated X Human genes 0.000 description 19
• 108700000707 bcl-2-Associated X Proteins 0.000 description 19
• 239000000047 product Substances 0.000 description 19
• 238000001415 gene therapy Methods 0.000 description 18
• 238000003752 polymerase chain reaction Methods 0.000 description 18
• 102000004169 proteins and genes Human genes 0.000 description 18
• 239000000126 substance Substances 0.000 description 18
• 210000000056 organ Anatomy 0.000 description 17
• 235000018102 proteins Nutrition 0.000 description 17
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
• 108091034117 Oligonucleotide Proteins 0.000 description 16
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 16
• 230000004048 modification Effects 0.000 description 16
• 238000012986 modification Methods 0.000 description 16
• 241000699666 Mus <mouse, genus> Species 0.000 description 15
• 238000013459 approach Methods 0.000 description 14
• 230000003247 decreasing effect Effects 0.000 description 14
• 230000006870 function Effects 0.000 description 14
• 239000003550 marker Substances 0.000 description 14
• 239000002245 particle Substances 0.000 description 14
• 238000003786 synthesis reaction Methods 0.000 description 14
• 210000004072 lung Anatomy 0.000 description 13
• 239000000523 sample Substances 0.000 description 13
• BJRCFZKVYNDCJE-WBSNEMHCSA-N 99489-95-9 Chemical group C([C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(=O)N2)[C@@H](C)CC)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC1=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C1=CC=C(O)C=C1 BJRCFZKVYNDCJE-WBSNEMHCSA-N 0.000 description 12
• 108050006400 Cyclin Proteins 0.000 description 12
• 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 12
• 238000009825 accumulation Methods 0.000 description 12
• 239000000443 aerosol Substances 0.000 description 12
• 230000018109 developmental process Effects 0.000 description 12
• 102000004039 Caspase-9 Human genes 0.000 description 11
• 108090000566 Caspase-9 Proteins 0.000 description 11
• 239000011230 binding agent Substances 0.000 description 11
• 150000001875 compounds Chemical class 0.000 description 11
• 108020001507 fusion proteins Proteins 0.000 description 11
• 102000037865 fusion proteins Human genes 0.000 description 11
• 230000012010 growth Effects 0.000 description 11
• 238000009396 hybridization Methods 0.000 description 11
• 108020004999 messenger RNA Proteins 0.000 description 11
• 238000013519 translation Methods 0.000 description 11
• 108091026890 Coding region Proteins 0.000 description 10
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
• 230000004663 cell proliferation Effects 0.000 description 10
• 230000008859 change Effects 0.000 description 10
• 238000012217 deletion Methods 0.000 description 10
• 230000037430 deletion Effects 0.000 description 10
• 238000003018 immunoassay Methods 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 150000003384 small molecules Chemical class 0.000 description 10
• 238000010561 standard procedure Methods 0.000 description 10
• 241000701161 unidentified adenovirus Species 0.000 description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• 206010016654 Fibrosis Diseases 0.000 description 9
• 241000700605 Viruses Species 0.000 description 9
• 125000000539 amino acid group Chemical group 0.000 description 9
• 239000003795 chemical substances by application Substances 0.000 description 9
• 230000004761 fibrosis Effects 0.000 description 9
• 238000003780 insertion Methods 0.000 description 9
• 230000037431 insertion Effects 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 210000005000 reproductive tract Anatomy 0.000 description 9
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
• 230000002159 abnormal effect Effects 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• 238000007792 addition Methods 0.000 description 8
• 230000001640 apoptogenic effect Effects 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 238000003776 cleavage reaction Methods 0.000 description 8
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 238000003209 gene knockout Methods 0.000 description 8
• 238000012545 processing Methods 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• 230000007017 scission Effects 0.000 description 8
• 238000012216 screening Methods 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 241000700159 Rattus Species 0.000 description 7
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
• 230000037396 body weight Effects 0.000 description 7
• 239000002299 complementary DNA Substances 0.000 description 7
• 230000008021 deposition Effects 0.000 description 7
• 230000004069 differentiation Effects 0.000 description 7
• 210000000936 intestine Anatomy 0.000 description 7
• 230000035935 pregnancy Effects 0.000 description 7
• 238000003259 recombinant expression Methods 0.000 description 7
• 230000001105 regulatory effect Effects 0.000 description 7
• 235000002639 sodium chloride Nutrition 0.000 description 7
• 238000013518 transcription Methods 0.000 description 7
• 230000035897 transcription Effects 0.000 description 7
• 238000012546 transfer Methods 0.000 description 7
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 6
• 108020004705 Codon Proteins 0.000 description 6
• 238000002965 ELISA Methods 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• 239000004365 Protease Substances 0.000 description 6
• 108020004511 Recombinant DNA Proteins 0.000 description 6
• 230000021736 acetylation Effects 0.000 description 6
• 238000006640 acetylation reaction Methods 0.000 description 6
• 150000007513 acids Chemical class 0.000 description 6
• QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 6
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 6
• 210000000170 cell membrane Anatomy 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 6
• 230000002950 deficient Effects 0.000 description 6
• 239000012636 effector Substances 0.000 description 6
• 230000005714 functional activity Effects 0.000 description 6
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
• 210000004408 hybridoma Anatomy 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 238000011813 knockout mouse model Methods 0.000 description 6
• 230000003902 lesion Effects 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 210000004962 mammalian cell Anatomy 0.000 description 6
• 238000002703 mutagenesis Methods 0.000 description 6
• 231100000350 mutagenesis Toxicity 0.000 description 6
• 108091008146 restriction endonucleases Proteins 0.000 description 6
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 6
• 210000002966 serum Anatomy 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 238000011282 treatment Methods 0.000 description 6
• 241000701447 unidentified baculovirus Species 0.000 description 6
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 108020004440 Thymidine kinase Proteins 0.000 description 5
• 238000010521 absorption reaction Methods 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 239000000074 antisense oligonucleotide Substances 0.000 description 5
• 238000012230 antisense oligonucleotides Methods 0.000 description 5
• 238000013270 controlled release Methods 0.000 description 5
• 230000000875 corresponding effect Effects 0.000 description 5
• 235000014113 dietary fatty acids Nutrition 0.000 description 5
• 230000002500 effect on skin Effects 0.000 description 5
• 229930195729 fatty acid Natural products 0.000 description 5
• 239000000194 fatty acid Substances 0.000 description 5
• 230000013595 glycosylation Effects 0.000 description 5
• 238000006206 glycosylation reaction Methods 0.000 description 5
• 238000000099 in vitro assay Methods 0.000 description 5
• 238000001990 intravenous administration Methods 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 230000026731 phosphorylation Effects 0.000 description 5
• 238000006366 phosphorylation reaction Methods 0.000 description 5
• 239000003380 propellant Substances 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 210000002863 seminiferous tubule Anatomy 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 230000002381 testicular Effects 0.000 description 5
• 230000007838 tissue remodeling Effects 0.000 description 5
• 102000007698 Alcohol dehydrogenase Human genes 0.000 description 4
• 108010021809 Alcohol dehydrogenase Proteins 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 241000283707 Capra Species 0.000 description 4
• 206010059866 Drug resistance Diseases 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 108090000526 Papain Proteins 0.000 description 4
• 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
• 102000006601 Thymidine Kinase Human genes 0.000 description 4
• 241000700618 Vaccinia virus Species 0.000 description 4
• 230000001594 aberrant effect Effects 0.000 description 4
• 239000003242 anti bacterial agent Substances 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 210000000481 breast Anatomy 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• 201000010099 disease Diseases 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 230000004927 fusion Effects 0.000 description 4
• 210000001035 gastrointestinal tract Anatomy 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
• 239000007922 nasal spray Substances 0.000 description 4
• 229940097496 nasal spray Drugs 0.000 description 4
• 239000002736 nonionic surfactant Substances 0.000 description 4
• 238000007899 nucleic acid hybridization Methods 0.000 description 4
• 235000019834 papain Nutrition 0.000 description 4
• 229940055729 papain Drugs 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• 108010079892 phosphoglycerol kinase Proteins 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 230000006337 proteolytic cleavage Effects 0.000 description 4
• 230000001177 retroviral effect Effects 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 210000000582 semen Anatomy 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 239000007790 solid phase Substances 0.000 description 4
• 239000000829 suppository Substances 0.000 description 4
• 239000004094 surface-active agent Substances 0.000 description 4
• 230000002103 transcriptional effect Effects 0.000 description 4
• 239000013603 viral vector Substances 0.000 description 4
• FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical class [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 3
• MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 3
• NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 3
• SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
• 108700028369 Alleles Proteins 0.000 description 3
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 108090000317 Chymotrypsin Proteins 0.000 description 3
• FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 3
• 241000702421 Dependoparvovirus Species 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 108010051815 Glutamyl endopeptidase Proteins 0.000 description 3
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 3
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 3
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
• 206010052437 Nasal discomfort Diseases 0.000 description 3
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
• 108010067902 Peptide Library Proteins 0.000 description 3
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 108010077895 Sarcosine Proteins 0.000 description 3
• 241000282887 Suidae Species 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 108090000631 Trypsin Proteins 0.000 description 3
• 102000004142 Trypsin Human genes 0.000 description 3
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 3
• 238000007818 agglutination assay Methods 0.000 description 3
• 230000009435 amidation Effects 0.000 description 3
• 238000007112 amidation reaction Methods 0.000 description 3
• 229960002684 aminocaproic acid Drugs 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 235000003704 aspartic acid Nutrition 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 239000013602 bacteriophage vector Substances 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 230000009134 cell regulation Effects 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 238000007385 chemical modification Methods 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 229960002376 chymotrypsin Drugs 0.000 description 3
• 229960002173 citrulline Drugs 0.000 description 3
• 235000013477 citrulline Nutrition 0.000 description 3
• 238000004440 column chromatography Methods 0.000 description 3
• 230000002860 competitive effect Effects 0.000 description 3
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 238000001212 derivatisation Methods 0.000 description 3
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 238000009509 drug development Methods 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 230000009144 enzymatic modification Effects 0.000 description 3
• 238000006911 enzymatic reaction Methods 0.000 description 3
• 210000005081 epithelial layer Anatomy 0.000 description 3
• 239000000262 estrogen Substances 0.000 description 3
• NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 3
• 230000022244 formylation Effects 0.000 description 3
• 238000006170 formylation reaction Methods 0.000 description 3
• 238000002825 functional assay Methods 0.000 description 3
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 229960002591 hydroxyproline Drugs 0.000 description 3
• 230000002390 hyperplastic effect Effects 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 239000000411 inducer Substances 0.000 description 3
• 238000005342 ion exchange Methods 0.000 description 3
• 230000007794 irritation Effects 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 230000002438 mitochondrial effect Effects 0.000 description 3
• 230000008520 organization Effects 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 230000003647 oxidation Effects 0.000 description 3
• 238000007254 oxidation reaction Methods 0.000 description 3
• 238000010647 peptide synthesis reaction Methods 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 230000003161 proteinsynthetic effect Effects 0.000 description 3
• 229940044601 receptor agonist Drugs 0.000 description 3
• 239000000018 receptor agonist Substances 0.000 description 3
• 229940044551 receptor antagonist Drugs 0.000 description 3
• 239000002464 receptor antagonist Substances 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000006722 reduction reaction Methods 0.000 description 3
• 229940043230 sarcosine Drugs 0.000 description 3
• ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 3
• 229940055619 selenocysteine Drugs 0.000 description 3
• 235000016491 selenocysteine Nutrition 0.000 description 3
• 238000002741 site-directed mutagenesis Methods 0.000 description 3
• 238000004513 sizing Methods 0.000 description 3
• 239000012279 sodium borohydride Substances 0.000 description 3
• 229910000033 sodium borohydride Inorganic materials 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 230000025366 tissue development Effects 0.000 description 3
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 230000001960 triggered effect Effects 0.000 description 3
• 239000012588 trypsin Substances 0.000 description 3
• ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 3
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 3
• 230000007306 turnover Effects 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical class OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 2
• RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
• FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
• OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
• OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
• 101710132601 Capsid protein Proteins 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 241000701489 Cauliflower mosaic virus Species 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 102100031780 Endonuclease Human genes 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 241000282560 Macaca mulatta Species 0.000 description 2
• 241000713333 Mouse mammary tumor virus Species 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 101710107068 Myelin basic protein Proteins 0.000 description 2
• HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 108010067372 Pancreatic elastase Proteins 0.000 description 2
• 208000000450 Pelvic Pain Diseases 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 2
• 241000714474 Rous sarcoma virus Species 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
• 241000282898 Sus scrofa Species 0.000 description 2
• 108090000848 Ubiquitin Proteins 0.000 description 2
• 102000044159 Ubiquitin Human genes 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 238000001261 affinity purification Methods 0.000 description 2
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 239000003708 ampul Substances 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 230000005775 apoptotic pathway Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 229960000074 biopharmaceutical Drugs 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 230000004087 circulation Effects 0.000 description 2
• 230000002301 combined effect Effects 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 210000004207 dermis Anatomy 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 229940011871 estrogen Drugs 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 238000012817 gel-diffusion technique Methods 0.000 description 2
• 230000001456 gonadotroph Effects 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• 230000003054 hormonal effect Effects 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 210000003016 hypothalamus Anatomy 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000000951 immunodiffusion Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 238000005462 in vivo assay Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 239000002085 irritant Substances 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 239000011859 microparticle Substances 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 210000000066 myeloid cell Anatomy 0.000 description 2
• 108010065781 myosin light chain 2 Proteins 0.000 description 2
• 230000036963 noncompetitive effect Effects 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 239000002853 nucleic acid probe Substances 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 210000004248 oligodendroglia Anatomy 0.000 description 2
• 208000008634 oligospermia Diseases 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 230000027758 ovulation cycle Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 102000013415 peroxidase activity proteins Human genes 0.000 description 2
• 108040007629 peroxidase activity proteins Proteins 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
• 230000000243 photosynthetic effect Effects 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 239000000186 progesterone Substances 0.000 description 2
• 229960003387 progesterone Drugs 0.000 description 2
• 230000009465 prokaryotic expression Effects 0.000 description 2
• 230000000644 propagated effect Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
• 239000003488 releasing hormone Substances 0.000 description 2
• 238000009877 rendering Methods 0.000 description 2
• 230000029058 respiratory gaseous exchange Effects 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• 230000005070 ripening Effects 0.000 description 2
• 210000000717 sertoli cell Anatomy 0.000 description 2
• 210000002027 skeletal muscle Anatomy 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 210000002536 stromal cell Anatomy 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000014621 translational initiation Effects 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 229960001322 trypsin Drugs 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 239000008096 xylene Substances 0.000 description 2
• CADQNXRGRFJSQY-UOWFLXDJSA-N (2r,3r,4r)-2-fluoro-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@@H](O)[C@@](O)(F)C=O CADQNXRGRFJSQY-UOWFLXDJSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
• HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
• MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
• HCYQTNUNMRYQLZ-UHFFFAOYSA-N 2-[(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)amino]acetic acid Chemical compound C(=O)(O)CNC=1C(NC(NC=1C)=O)=O HCYQTNUNMRYQLZ-UHFFFAOYSA-N 0.000 description 1
• XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
• SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
• VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
• GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
• MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
• LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
• VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
• ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
• KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
• KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
• ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 241001156002 Anthonomus pomorum Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 241000581364 Clinitrachus argentatus Species 0.000 description 1
• 108020004394 Complementary RNA Proteins 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 102000005927 Cysteine Proteases Human genes 0.000 description 1
• 108010005843 Cysteine Proteases Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 239000004287 Dehydroacetic acid Substances 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 108010067770 Endopeptidase K Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 102100039555 Galectin-7 Human genes 0.000 description 1
• 241000272496 Galliformes Species 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 101000887163 Gallus gallus Gallinacin-4 Proteins 0.000 description 1
• 101000887166 Gallus gallus Gallinacin-7 Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000006771 Gonadotropins Human genes 0.000 description 1
• 108010086677 Gonadotropins Proteins 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101001091088 Homo sapiens Prorelaxin H2 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
• 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
• 208000005137 Joint instability Diseases 0.000 description 1
• 206010023421 Kidney fibrosis Diseases 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• 150000008575 L-amino acids Chemical class 0.000 description 1
• QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
• 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 229920002884 Laureth 4 Polymers 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 206010024825 Loose associations Diseases 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
• AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241000237988 Patellidae Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920002507 Poloxamer 124 Polymers 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 102100034949 Prorelaxin H2 Human genes 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 1
• 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 1
• 206010037423 Pulmonary oedema Diseases 0.000 description 1
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
• 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 108090000783 Renin Proteins 0.000 description 1
• 208000036071 Rhinorrhea Diseases 0.000 description 1
• 206010039101 Rhinorrhoea Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 108091058545 Secretory proteins Proteins 0.000 description 1
• 102000040739 Secretory proteins Human genes 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 101710137500 T7 RNA polymerase Proteins 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010047141 Vasodilatation Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 208000021096 adenomatous colon polyp Diseases 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 150000001408 amides Chemical group 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 238000003782 apoptosis assay Methods 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 210000001142 back Anatomy 0.000 description 1
• 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 230000007885 bronchoconstriction Effects 0.000 description 1
• 230000003182 bronchodilatating effect Effects 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
• 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 208000027744 congestion Diseases 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000005289 controlled pore glass Substances 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000016117 decidualization Effects 0.000 description 1
• 235000019258 dehydroacetic acid Nutrition 0.000 description 1
• JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
• 229940061632 dehydroacetic acid Drugs 0.000 description 1
• PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000035252 development of secondary sexual characteristics Effects 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 210000001163 endosome Anatomy 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000003172 expectorant agent Substances 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 102000036444 extracellular matrix enzymes Human genes 0.000 description 1
• 108091007167 extracellular matrix enzymes Proteins 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000035558 fertility Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 230000000799 fusogenic effect Effects 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• 230000006543 gametophyte development Effects 0.000 description 1
• IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
• 229960002963 ganciclovir Drugs 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000000745 gonadal hormone Substances 0.000 description 1
• 239000002622 gonadotropin Substances 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000035931 haemagglutination Effects 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• 239000004009 herbicide Substances 0.000 description 1
• 150000002402 hexoses Chemical class 0.000 description 1
• 230000036732 histological change Effects 0.000 description 1
• 238000010562 histological examination Methods 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000000760 immunoelectrophoresis Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 238000003017 in situ immunoassay Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 210000004020 intracellular membrane Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 231100000021 irritant Toxicity 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 229940062711 laureth-9 Drugs 0.000 description 1
• 150000002611 lead compounds Chemical class 0.000 description 1
• 238000007834 ligase chain reaction Methods 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000029849 luteinization Effects 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 230000006674 lysosomal degradation Effects 0.000 description 1
• 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000008176 mammary development Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
• HPZMWTNATZPBIH-UHFFFAOYSA-N methyl adenine Natural products CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 125000000250 methylamino group Chemical class [H]N(*)C([H])([H])[H] 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000008965 mitochondrial swelling Effects 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 229940066491 mucolytics Drugs 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 239000003471 mutagenic agent Substances 0.000 description 1
• 231100000707 mutagenic chemical Toxicity 0.000 description 1
• XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
• 210000002850 nasal mucosa Anatomy 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
• 230000037311 normal skin Effects 0.000 description 1
• 238000001668 nucleic acid synthesis Methods 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000005305 organ development Effects 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 238000004091 panning Methods 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 230000032696 parturition Effects 0.000 description 1
• 235000015927 pasta Nutrition 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
• 230000037050 permeability transition Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000000575 pesticide Substances 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 238000009520 phase I clinical trial Methods 0.000 description 1
• 150000002989 phenols Chemical class 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229940093448 poloxamer 124 Drugs 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229960003975 potassium Drugs 0.000 description 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
• 235000010235 potassium benzoate Nutrition 0.000 description 1
• 239000004300 potassium benzoate Substances 0.000 description 1
• 229940103091 potassium benzoate Drugs 0.000 description 1
• RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
• 229940043349 potassium metabisulfite Drugs 0.000 description 1
• 235000010263 potassium metabisulphite Nutrition 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 108010090955 preprorelaxin Proteins 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 108010087851 prorelaxin Proteins 0.000 description 1
• 210000005267 prostate cell Anatomy 0.000 description 1
• 238000013197 protein A assay Methods 0.000 description 1
• 208000005333 pulmonary edema Diseases 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000034846 regulation of tissue remodeling Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 229920000260 silastic Polymers 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 229940001607 sodium bisulfite Drugs 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 230000019100 sperm motility Effects 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000008227 sterile water for injection Substances 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229940044609 sulfur dioxide Drugs 0.000 description 1
• 235000010269 sulphur dioxide Nutrition 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 230000008467 tissue growth Effects 0.000 description 1
• 230000030968 tissue homeostasis Effects 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 230000009452 underexpressoin Effects 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 230000008347 uteroplacental blood flow Effects 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 229940075420 xanthine Drugs 0.000 description 1